Undisclosed second generation c-abl inhibitor / Inhibikase - LARVOL DELTA

Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib - "Inhibikase Therapeutics, Inc...is evaluating new molecules with multiple mechanisms of action for c-Abl inhibition. Along with the development of new molecules, IkT-148009 has now been granted the non-proprietary name of risvodetinib (or 'risvo')....'In addition, we are evaluating early stage molecules from other companies that inhibit c-Abl without binding to the enzyme active site. Such novel inhibitors, alone or in combination with active site inhibitors like IkT-148009, may be an improved approach to suppress neurodegeneration arising from c-Abl activation inside and outside of the brain.'"

Clinical • Preclinical • CNS Disorders • Parkinson's Disease